Spinal cord stimulation for painful neuropathy now has a nerve fibre signal behind it

Design

multicentre randomised controlled trial, 1:1, open-label intervention with allocation-blinded sensory and nerve fibre assessment

Population

91 adults with painful diabetic neuropathy — 41 to 10 kHz spinal cord stimulation plus medical management, 50 to medical management alone

Primary outcome

proportion achieving ≥50% lower-limb pain relief at 6 months

Effect

27 of 34 stimulated versus 2 of 50 control (p<0.001); sensory score improvement 55.2% versus 25.0% (p=0.01); nerve fibre density +0.58 versus −0.07 fibres/mm (p=0.03)

PDN-Sensory randomised 91 people with painful diabetic neuropathy to conventional medical management alone or high-frequency 10 kHz spinal cord stimulation added to it. Pain relief with this device was already known. What this trial went after was objective sensory change, with the modified Toronto Clinical Neuropathy Score and intraepidermal nerve fibre density assessed blind to allocation.

The pain result was emphatic: in a worst-case intention-to-treat analysis, 27 of 34 stimulated participants who had a temporary trial achieved at least 50% lower-limb pain relief, against 2 of 50 on medical management alone. Sensory improvement on the neuropathy score occurred in 55.2% versus 25.0% at six months. Mean lower-calf nerve fibre density rose by 0.58 fibres/mm with stimulation and fell by 0.07 without. Eight of ten hierarchical secondary endpoints were met, including sleep and quality of life.

A rising nerve fibre density in a disease that only ever takes fibres away is a genuinely unusual result, and the blinding of that assessment is what makes it worth reporting. It is also six months, in 91 people, with an unblinded intervention that involves an implant. The pain and sleep benefits are solid enough to act on; disease modification is a hypothesis this trial has made worth testing, not a conclusion.

• Identify the patients this is for: refractory painful neuropathy after adequate trials of the standard oral agents, not first-line therapy.
• A temporary trial period precedes implantation — the response rate quoted here is among those who reached that stage.
• Set the expectation as pain, sleep and function; do not offer nerve regeneration as a reason to proceed.
• Availability in India is limited to a few tertiary pain and neuromodulation centres, and the device cost is rarely reimbursed — establish that before raising it with a patient.
• Keep glycaemic management, foot care and pain pharmacotherapy running alongside; this was tested as an addition to medical management, not a replacement.

Why it matters

Every existing treatment for this condition manages the symptom; this is the first randomised signal that the nerve itself might respond.

Don't overread it

Six months in 91 people with an unblinded intervention does not establish disease modification — the nerve fibre change is a prespecified marker, not proof the neuropathy was altered.

The statistics, in plain English

The comparison of 27 of 34 against 2 of 50 is so wide that chance is not a plausible explanation, but the denominators differ in an important way: the stimulation figure counts those who reached a temporary trial, so it describes response among patients who got that far rather than among everyone randomised. The nerve fibre difference of 0.58 versus −0.07 fibres/mm is small in absolute terms and is a biological marker, not an outcome a patient experiences — its value is that it points in a direction nothing else in this disease does.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.